[go: up one dir, main page]

MX2020012081A - Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. - Google Patents

Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.

Info

Publication number
MX2020012081A
MX2020012081A MX2020012081A MX2020012081A MX2020012081A MX 2020012081 A MX2020012081 A MX 2020012081A MX 2020012081 A MX2020012081 A MX 2020012081A MX 2020012081 A MX2020012081 A MX 2020012081A MX 2020012081 A MX2020012081 A MX 2020012081A
Authority
MX
Mexico
Prior art keywords
antibodies
fully human
antibodies against
methods
human antibodies
Prior art date
Application number
MX2020012081A
Other languages
English (en)
Inventor
Jing Li
Yong Zheng
Baotian Yang
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of MX2020012081A publication Critical patent/MX2020012081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud proporciona anticuerpos monoclonales completamente humanos contra la superfamilia del receptor del factor de necrosis tumoral, miembro 4 (TNFRSF4), tambien conocido como OX40 y CD134. Tambien proporciona los metodos de generacion de hibridomas utilizando una rata transgenica humanizada, las moleculas de acido nucleico que codifican los anticuerpos anti-OX40, los vectores de expresion y las celulas huesped utilizadas para la expresion de anticuerpos anti-OX40. La invencion proporciona ademas los metodos para validar la funcion de los anticuerpos in vitro y la eficacia de los anticuerpos in vivo. Los anticuerpos de la invencion proporcionan un agente muy potente para el tratamiento de multiples canceres que modulan la funcion inmune humana.
MX2020012081A 2018-05-11 2019-05-07 Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. MX2020012081A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018086574 2018-05-11
CN201810529840 2018-05-29
PCT/CN2019/085886 WO2019214624A1 (en) 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof

Publications (1)

Publication Number Publication Date
MX2020012081A true MX2020012081A (es) 2021-04-28

Family

ID=68466901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012081A MX2020012081A (es) 2018-05-11 2019-05-07 Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.

Country Status (12)

Country Link
US (1) US20210171647A1 (es)
EP (2) EP4074732A1 (es)
JP (1) JP7411575B2 (es)
KR (1) KR20210039986A (es)
CN (2) CN110467674B (es)
AU (1) AU2019264712A1 (es)
BR (1) BR112020023026A2 (es)
CA (1) CA3103040A1 (es)
MX (1) MX2020012081A (es)
SG (1) SG11202011201QA (es)
TW (1) TWI831778B (es)
WO (1) WO2019214624A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797123A4 (en) 2018-05-23 2022-03-02 BeiGene, Ltd. ANTI-OX40 ANTIBODIES AND METHODS OF USE
JP2023503229A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド 抗ｏｘ４０抗体とマルチキナーゼ阻害剤とによる癌の治療
WO2021115240A1 (zh) * 2019-12-13 2021-06-17 四川科伦博泰生物医药股份有限公司 抗tslp抗体及其用途
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN111153994B (zh) * 2019-12-31 2021-10-15 武汉班科生物技术股份有限公司 人肿瘤坏死因子的人源单克隆抗体
CN113135994A (zh) * 2020-01-19 2021-07-20 迈威(上海)生物科技股份有限公司 一种激活型抗ox40抗体、生产方法及应用
WO2021190431A1 (zh) * 2020-03-23 2021-09-30 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN111518209B (zh) * 2020-05-09 2023-07-25 郑州航空港百桥生物科技有限公司 特异性结合人ox40的单克隆抗体及其应用
TW202229352A (zh) * 2020-11-12 2022-08-01 大陸商同潤生物醫藥(上海)有限公司 聯合治療及其使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2307832T3 (es) 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
DK2242771T3 (da) 2007-12-14 2013-08-26 Pfizer Bindingsmolekyler til den humane ox40-receptor
AP2013006771A0 (en) * 2010-08-23 2013-03-31 Boards Of Regents The University Of Texas System Anti-OX40 antibodies and methods of using the same
CA3158257A1 (en) * 2011-07-11 2013-01-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP2931030B2 (en) 2012-12-14 2024-01-17 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
DK2976361T3 (en) 2013-03-18 2018-10-01 Biocerox Prod Bv HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
TWI671317B (zh) * 2013-08-02 2019-09-11 輝瑞大藥廠 抗ｃｘｃｒ４抗體及抗體-藥物結合物
CN106103486B (zh) 2014-03-31 2020-04-21 豪夫迈·罗氏有限公司 抗ox40抗体和使用方法
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
EA201792451A1 (ru) 2015-05-07 2018-05-31 Агенус Инк. Антитела к ox40 и способы их применения
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
MX2017014740A (es) * 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
JP6771551B2 (ja) 2015-10-15 2020-10-21 ディンフー バイオターゲット カンパニー リミテッド 抗ｏｘ４０抗体及びその応用
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
CA3033661A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN107815465B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用

Also Published As

Publication number Publication date
BR112020023026A2 (pt) 2021-02-09
TW202003575A (zh) 2020-01-16
TWI831778B (zh) 2024-02-11
AU2019264712A1 (en) 2021-01-07
CN110467674B (zh) 2022-05-31
CA3103040A1 (en) 2019-11-14
EP3790903A1 (en) 2021-03-17
KR20210039986A (ko) 2021-04-12
CN114685665B (zh) 2025-02-14
SG11202011201QA (en) 2020-12-30
EP3790903A4 (en) 2022-06-08
EP4074732A1 (en) 2022-10-19
JP7411575B2 (ja) 2024-01-11
JP2021522847A (ja) 2021-09-02
CN114685665A (zh) 2022-07-01
US20210171647A1 (en) 2021-06-10
WO2019214624A1 (en) 2019-11-14
CN110467674A (zh) 2019-11-19

Similar Documents

Publication Publication Date Title
MX2020012081A (es) Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
MY205758A (en) Anti-nkg2a antibodies and uses thereof
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
EP4464333A3 (en) Anti-death receptor antibodies and methods of use thereof
CR20200567A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
PH12018501554A1 (en) Ror1 antibody compositions and related methods
WO2016150899A3 (en) Anti-ceacam6 antibodies and uses thereof
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
ZA202202363B (en) Antibodies against ilt2 and use thereof
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
FI3303396T3 (fi) Vasta-aineita ox40:ää vastaan ja niiden käyttöjä
EA202091747A1 (ru) Составы антитела b7-h4
ZA201901379B (en) Antigen binding protein against her3
CN109963592A (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
CR20200391A (es) Moléculas biespecíficas de unión al antígeno y métodos de uso
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
ZA202302392B (en) Antibodies against ilt2 and use thereof
WO2017060322A3 (en) Ptefb-inhibitor-adc
CR20200463A (es) Anticuerpos
EA202090791A1 (ru) Агонистические антитела против cd40
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.